Ovarian Cancer Clinical Trials


Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions:   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions:   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
Sponsors:   University of Washington;   National Cancer Institute (NCI)
Recruiting - verified July 2017

Learn More

An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery

Condition:   Ovary Cancer
Interventions:   Drug: EC1456;   Drug: 99mTc-Etarfolatide
Sponsor:   Endocyte
Recruiting - verified July 2017

Learn More

A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications

Conditions:   Colorectal Cancer (CRC);   Ovarian Cancer (Epithelial and Fallopian Tube );   Urothelial Carcinoma;   Triple-negative Breast Cancer (TNBC);   Pancreatic Cancer;   Acute Myeloid Leukemia/Myelodysplastic Syndrome;   Multiple Myeloma (MM)
Intervention:   Biological: NKR-2 cells
Sponsor:   Celyad (formerly named Cardio3 BioSciences)
Recruiting - verified July 2017

Learn More

Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cancer
Intervention:   Biological: Autologous Monocytes + ACTIMMUNE + SYLATRON
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified July 11, 2017

Learn More

Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma

Condition:   Ovarian Cancer
Intervention:   Biological: OncoImmunome
Sponsor:   UConn Health
Recruiting - verified July 2017

Learn More

Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes

Conditions:   Ovarian Cancer;   Prostate Cancer;   Pancreas Cancer
Intervention:   Behavioral: Assessments
Sponsor:   Memorial Sloan Kettering Cancer Center
Recruiting - verified July 2017

Learn More

A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors

Conditions:   Advanced Cancer;   Metastatic Cancer
Intervention:   Drug: INCAGN01949
Sponsor:   Incyte Biosciences International Sàrl
Recruiting - verified July 2017

Learn More

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Conditions:   Estrogen Receptor Negative;   HER2/Neu Negative;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Metastatic Malignant Solid Neoplasm;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Triple-Negative Breast Carcinoma;   Unresectable Solid Neoplasm
Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Drug: Onalespib;   Other: Pharmacological Study
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified July 2017

Learn More

A Phase II Study Of Nivolumab/ Bevacizumab

Conditions:   Peritoneal Cancer;   Ovarian Cancer;   Fallopian Tube Cancer
Interventions:   Drug: Bevacizumab;   Drug: Nivolumab
Sponsors:   Dana-Farber Cancer Institute;   Bristol-Myers Squibb
Recruiting - verified July 2017

Learn More

Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer

Condition:   Recurrent Platinum Resistant Ovarian Cancer
Intervention:   Drug: cediranib and olaparib
Sponsors:   AstraZeneca;   Myriad Genetic Laboratories, Inc.
Recruiting - verified July 2017

Learn More

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Quality-of-Life Assessment
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified July 2017

Learn More

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions:   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Recombinant NY-ESO-1 Protein;   Drug: Sirolimus
Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Not yet recruiting - verified May 2017

Learn More

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Conditions:   Acinar Cell Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Dermoid Cyst;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Undifferentiated Gastric Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Adenocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified May 2017

Learn More

Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer

Condition:   Ovarian Neoplasms
Interventions:   Drug: Anetumab ravtansine (BAY94-9343);   Drug: Pegylated Liposomal Doxorubicin
Sponsor:   Bayer
Recruiting - verified July 2017

Learn More

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer

Conditions:   Malignant Neoplasms of Female Genital Organs;   Ovarian Cancer;   Primary Peritoneal Carcinoma;   Fallopian Tube Cancer
Interventions:   Drug: Durvalumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Behavioral: Questionnaires;   Procedure: Debulking Surgery
Sponsors:   M.D. Anderson Cancer Center;   AstraZeneca
Recruiting - verified July 2017

Learn More

31-45 of 69
Results per page

Join the community!


You must be a member of healtheo360 in order to view this group

Register with Email Address

Already a member? Click here to login

healtheo360 believes strongly in user privacy.